Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
GlaxoSmithKline PLC A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.	United Kingdom	GSK
GL Pharm Tech Corp. Develops improved drugs and generics, and licenses proprietary drug formulation technologies.	South Korea	204840
GNI Group Ltd. Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.	Japan	2160
Goodwill Pharma Plc Integrated pharma CDMO developing Rx/OTC meds, supplements & devices for CEE markets.	Hungary	GWPH
Gossamer Bio, Inc. Clinical-stage biopharma developing inhaled therapies for rare pulmonary hypertension.	United States of America	GOSS
Grace Therapeutics, Inc. Develops improved drugs for rare neurological diseases using novel drug delivery technologies.	United States of America	GRCE
Green Cross Holdings A biotech firm in biopharma, diagnostics, digital health, and consumer wellness products.	South Korea	005250
GREEN CROSS WellBeing Corporation Develops personalized nutrition solutions, from prescription injections to supplements & cosmetics.	South Korea	234690
Greenwich LifeSciences, Inc. Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.	United States of America	GLSI
GRI Bio, Inc. Advancing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.	United States of America	GRI